Drug intelligence / Profile preview

AR-1105 CF2

Development stage: Unknown
Lead developer: Alcon
Modality: Small Molecules
Administration: Intravitreal

Overview

AR-1105 CF2 is a novel biodegradable sustained-release intravitreal dexamethasone implant designed to provide 6-month durability for treating macular edema due to retinal vein occlusion. It is one of two formulations (CF1 and CF2) evaluated in the ORION-1 Phase 2 clinical trial. The implant contains 340μg of dexamethasone combined with a mixture of three poly D, L-lactic-co-glycolic acid polymers that undergo slow erosion to deliver extended therapy. CF2 demonstrated a longer overall duration of effect compared to CF1, with sustained improvements in vision and reduction in retinal thickening for up to six months.

Other names: Clinical Formulation 2

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on AR-1105 CF2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR-1105 CF2.

Explore the full profile